Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?

被引:9
作者
Guardado Sanchez, L. A. [1 ,3 ,5 ]
Redondo, A. M. [2 ,3 ]
Blanco Munez, O. [3 ,4 ]
Sebastian, E. [2 ,3 ]
Alcoceba, M. [2 ,3 ]
Gonzalez, M. [2 ,3 ]
Martin, A. [2 ,3 ]
Caballero, D. [2 ,3 ]
机构
[1] Complejo Hosp Salamanca, Dept ENT & Haematol, Salamanca 37007, Spain
[2] Hosp Univ Salamanca, Dept Haematol, Salamanca, Spain
[3] IBSAL, Salamanca, Spain
[4] Hosp Univ Salamanca, Dept Pathol, Salamanca, Spain
[5] Hosp Univ Salamanca, Dept ENT, Salamanca, Spain
关键词
Head and neck; Extranodal vs. nodal; Diffuse large B cell lymphoma; Immunohistochemistry; Rituximab; NON-HODGKINS-LYMPHOMA; GERMINAL CENTER; PROGNOSTIC-SIGNIFICANCE; WALDEYERS RING; CLINICOPATHOLOGICAL FEATURES; CLINICAL-SIGNIFICANCE; PROTEIN EXPRESSION; SURVIVAL; IMPACT; BCL2;
D O I
10.1007/s00277-014-2256-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study analyzes patients with head and neck diffuse large B cell lymphoma (HN-DLBCL), focusing on the differences in the biological characteristics and prognosis of lymphomas of nodal and extranodal origin. We have included 72 patients with stage I-II HN-DLBCL who had updated survival information and diagnostic paraffin-embedded tissue blocks available for review. Non-germinal center phenotype (73.7 vs. 32.4 %, P = 0.001) and high level of Bcl-2 expression (78.9 vs. 52.9 %, P = 0.025) were more frequent in nodal than extranodal lymphomas. Univariate analyses indicated that bulky disease, Ann Arbor stage II, high level of Ki-67 expression, and primary nodal disease had adverse effects on complete remission (CR), but these effects were confirmed in a multivariate analysis for primary nodal disease and bulky disease. Patients with primary extranodal lymphoma also had better overall survival (OS) (87.7 vs. 72.5 %, P = 0.04) and event-free survival (EFS) (84 vs. 58.5 %, P = 0.046) than patients with nodal disease, although in the multivariate analysis, only Ann Arbor stage II continued to predict worse OS and EFS, whereas bulky disease was an independent prognostic factor only for EFS. We found significant differences in the biological characteristics and prognosis between primary nodal and extranodal HN-DLBCL.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 40 条
  • [11] Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study
    Hill, ME
    MacLennan, KA
    Cunningham, DC
    Hudson, BV
    Burke, M
    Clarke, P
    DiStefano, F
    Anderson, L
    Hudson, GV
    Mason, D
    Selby, P
    Linch, DC
    [J]. BLOOD, 1996, 88 (03) : 1046 - 1051
  • [12] BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
    Iqbal, J
    Neppalli, VT
    Wright, G
    Dave, LJ
    Horsman, DE
    Rosenwald, A
    Lynch, J
    Hans, CP
    Weisenburger, DD
    Greiner, TC
    Gascoyne, RD
    Campo, E
    Ott, G
    Müller-Hermelink, HK
    Delabie, J
    Jaffe, ES
    Grogan, TM
    Connors, JM
    Vose, JM
    Armitage, JO
    Staudt, LM
    Chan, WC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 961 - 968
  • [13] BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
    Iqbal, J
    Sanger, WG
    Horsman, DE
    Rosenwald, A
    Pickering, DL
    Dave, B
    Dave, S
    Xiao, L
    Cao, KJ
    Zhu, QM
    Sherman, S
    Hans, CP
    Weisenburger, DD
    Greiner, TC
    Gascoyne, RD
    Ott, G
    Müller-Hermelink, HK
    Delabie, J
    Braziel, RM
    Jaffe, ES
    Campo, E
    Lynch, JC
    Connors, JM
    Vose, JM
    Armitage, JO
    Grogan, TM
    Staudt, LM
    Chan, WC
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (01) : 159 - 166
  • [14] Jazirehi AR, 2005, CANCER RES, V65, P264
  • [15] Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma -: a Nordic Lymphoma Group study
    Jerkeman, M
    Anderson, H
    Dictor, M
    Kvaloy, S
    Åkerman, M
    Cavallin-Ståhl, E
    [J]. ANNALS OF HEMATOLOGY, 2004, 83 (07) : 414 - 419
  • [16] Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study
    Kramer, MHH
    Hermans, J
    Parker, J
    Krol, ADG
    KluinNelemans, JC
    Haak, HL
    vanGroningen, K
    vanKrieken, JHJM
    deJong, D
    Kluin, PM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2131 - 2138
  • [17] Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma
    Kramer, MHH
    Hermans, J
    Wijburg, E
    Philippo, K
    Geelen, E
    van Krieken, JHJM
    de Jong, D
    Maartense, E
    Schuuring, E
    Kluin, PM
    [J]. BLOOD, 1998, 92 (09) : 3152 - 3162
  • [18] Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry
    Krol, ADG
    le Cessie, S
    Snijder, S
    Kluin-Nelemans, JC
    Kluin, PM
    Noordijk, EM
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (01) : 131 - 139
  • [19] Waldeyer's ring lymphomas: A clinical study from the comprehensive cancer center west population based NHL registry
    Krol, ADG
    Le Cessie, S
    Snijder, S
    Kluin-Nelemans, JC
    Kluin, PM
    Noordijk, EM
    [J]. LEUKEMIA & LYMPHOMA, 2001, 42 (05) : 1005 - 1013
  • [20] High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy
    Li, Zhi-Ming
    Huang, Jia-Jia
    Xia, Yi
    Zhu, Ying-Jie
    Zhao, Wei
    Wei, Wen-Xiao
    Jiang, Wen-Qi
    Lin, Tong-Yu
    Huang, Hui-Qiang
    Guan, Zhong-Zhen
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (06) : 510 - 517